MX2020003507A - Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos. - Google Patents
Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos.Info
- Publication number
- MX2020003507A MX2020003507A MX2020003507A MX2020003507A MX2020003507A MX 2020003507 A MX2020003507 A MX 2020003507A MX 2020003507 A MX2020003507 A MX 2020003507A MX 2020003507 A MX2020003507 A MX 2020003507A MX 2020003507 A MX2020003507 A MX 2020003507A
- Authority
- MX
- Mexico
- Prior art keywords
- tbk
- ikk
- pyrimidine
- inhibitor compounds
- inhibitor
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573251P | 2017-10-17 | 2017-10-17 | |
| PCT/US2018/056190 WO2019079373A1 (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE TBK / IKKε INHIBITORY COMPOUNDS AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003507A true MX2020003507A (es) | 2020-07-22 |
Family
ID=64110185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003507A MX2020003507A (es) | 2017-10-17 | 2018-10-17 | Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230019491A1 (https=) |
| EP (1) | EP3697772A1 (https=) |
| JP (1) | JP7266592B2 (https=) |
| KR (1) | KR20200072519A (https=) |
| CN (1) | CN111247135A (https=) |
| AU (1) | AU2018352699A1 (https=) |
| BR (1) | BR112020007466A2 (https=) |
| CA (1) | CA3078579A1 (https=) |
| IL (1) | IL273891A (https=) |
| MX (1) | MX2020003507A (https=) |
| RU (1) | RU2020115596A (https=) |
| SG (1) | SG11202003407VA (https=) |
| TW (1) | TWI802604B (https=) |
| WO (1) | WO2019079373A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018352701A1 (en) * | 2017-10-17 | 2020-06-04 | Merck Patent Gmbh | Pyrimidine ΤΒΚ/ΙΚΚE inhibitor compounds and uses thereof |
| AU2019280689B2 (en) | 2018-06-05 | 2024-09-05 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| CN112552280A (zh) * | 2019-09-25 | 2021-03-26 | 常州强力先端电子材料有限公司 | 一种高产酸的磺酰亚胺类光产酸剂 |
| US12479825B2 (en) | 2019-11-07 | 2025-11-25 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof |
| CA3164117A1 (en) | 2019-12-18 | 2021-06-24 | Crinetics Pharmaceuticals, Inc. | Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| ES3032933T3 (en) | 2019-12-23 | 2025-07-29 | Crinetics Pharmaceuticals Inc | Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| AU2022240609A1 (en) | 2021-03-19 | 2023-09-28 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease |
| CN117447407B (zh) * | 2023-12-19 | 2024-06-11 | 潍坊医学院 | 一种JAK2抑制剂Pacritinib及其中间体的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2911139A1 (fr) * | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| JP5611826B2 (ja) * | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| EP2488503A1 (en) * | 2009-10-12 | 2012-08-22 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon |
| GB201012105D0 (en) * | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| MX2013011908A (es) * | 2011-04-12 | 2014-03-27 | Alzheimer S Inst Of America Inc | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. |
| DE102011112978A1 (de) * | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
| MX2017015357A (es) * | 2015-06-29 | 2018-03-16 | Merck Patent Gmbh | Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos. |
-
2018
- 2018-10-17 SG SG11202003407VA patent/SG11202003407VA/en unknown
- 2018-10-17 CA CA3078579A patent/CA3078579A1/en active Pending
- 2018-10-17 AU AU2018352699A patent/AU2018352699A1/en not_active Abandoned
- 2018-10-17 TW TW107136567A patent/TWI802604B/zh not_active IP Right Cessation
- 2018-10-17 EP EP18797386.2A patent/EP3697772A1/en not_active Withdrawn
- 2018-10-17 BR BR112020007466-7A patent/BR112020007466A2/pt not_active IP Right Cessation
- 2018-10-17 CN CN201880067979.0A patent/CN111247135A/zh active Pending
- 2018-10-17 US US16/756,769 patent/US20230019491A1/en not_active Abandoned
- 2018-10-17 KR KR1020207014078A patent/KR20200072519A/ko not_active Withdrawn
- 2018-10-17 MX MX2020003507A patent/MX2020003507A/es unknown
- 2018-10-17 WO PCT/US2018/056190 patent/WO2019079373A1/en not_active Ceased
- 2018-10-17 RU RU2020115596A patent/RU2020115596A/ru unknown
- 2018-10-17 JP JP2020521968A patent/JP7266592B2/ja active Active
-
2020
- 2020-04-07 IL IL273891A patent/IL273891A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3697772A1 (en) | 2020-08-26 |
| US20230019491A1 (en) | 2023-01-19 |
| RU2020115596A3 (https=) | 2021-11-18 |
| CA3078579A1 (en) | 2019-04-25 |
| BR112020007466A2 (pt) | 2020-09-24 |
| TWI802604B (zh) | 2023-05-21 |
| RU2020115596A (ru) | 2021-11-18 |
| JP2020537671A (ja) | 2020-12-24 |
| TW201922735A (zh) | 2019-06-16 |
| CN111247135A (zh) | 2020-06-05 |
| AU2018352699A1 (en) | 2020-05-28 |
| SG11202003407VA (en) | 2020-05-28 |
| KR20200072519A (ko) | 2020-06-22 |
| JP7266592B2 (ja) | 2023-04-28 |
| WO2019079373A1 (en) | 2019-04-25 |
| IL273891A (en) | 2020-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003507A (es) | Compuestos pirimidinicos inhibidores de (tbk)/(ikk) epsilon y usos de los mismos. | |
| ZA201907485B (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| GEP20217234B (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| MX2020003441A (es) | Transmision de referencia de sondeo. | |
| MX2020004287A (es) | Procesamiento de biomasa. | |
| MX2020003430A (es) | Derivados de 1-bencil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de proteasa de virus de inmunodeficiencia humana. | |
| MX2020003706A (es) | Aminoimidazopiridazinas como inhibidores de cinasa. | |
| MX2020003760A (es) | Formulaciones de niraparib. | |
| MX2017000363A (es) | Inhibicion de la via de notch. | |
| TWD187679S (zh) | 手槍 | |
| TWD188340S (zh) | 手槍 | |
| EA201691916A1 (ru) | Биарильные ингибиторы киназы | |
| MX2020004424A (es) | Formulacion aerosolizable. | |
| MX2020004071A (es) | Derivados de aztreonam y usos de los mismos. | |
| AU363883S (en) | Tracking device | |
| MX2020004455A (es) | Derivados de pirrolopirazina como inhibidores de integrina alfa v. | |
| MX2020004227A (es) | Estructura plana termicamente fijable. | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| MX2020003768A (es) | Composiciones acuosas herbicidas y metodos para usar las mismas. | |
| ECSDI17024111S (es) | Recipiente | |
| MX2020002908A (es) | Composicion acuosa de polimeros. | |
| IN2013CH06085A (https=) | ||
| MX2020003487A (es) | Compuestos inhibidores de pirimidina tbk/ikkepsilon y usos de los mismos. | |
| MX2020003578A (es) | Sal de edaravone. | |
| PL411823A1 (pl) | Ustnik do picia z puszki |